Tagged with oncology,

France Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this field, with a number of companies, institutes and hospitals pioneering new forms of treatment and adapting policy to fit the…

Ireland Darren Cunningham tells us the story behind Inflection Biosciences (and its name), the rationale of focusing on small molecule cancer treatments, his thoughts on the Irish biotech start-up scene, and his hopes for the company’s future development. Can you first provide an introduction to Inflection Biosciences to our international audience? “The Irish…

Singapore The CEO of ASLAN Pharmaceuticals, Dr. Carl Firth discusses the implications surrounding the company’s imminent initial public offering on Taiwan’s stock exchange, while explaining how this move serves to position ASLAN as Singapore’s first local success story. Having just completed a pre-IPO financing round, it seems the company has many…

Mexico Alvaro Angel, the recently appointed general manager of the pharmaceutical division of Bayer Mexico, provides insights into the rapidly evolving local pharma market, and documents Bayer Mexico’s ambitious growth strategy; with the affiliate already standing out as one of the most important of the group at a global level. You…

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…

Switzerland As the home market, Switzerland and Roche’s Swiss pharma operations play an important and pioneering role within Roche’s global organization, with early patient access to innovation and new commercial models taking place in the country. The working title of the Healthcare & Life Science Review Switzerland is “A Leader Among…

Luxembourg Marc Diederich, Director of the LBMCC and principal investigator conducting independent research, leading and training a 25-person group including PhD and MSc students, runs us through the raison d’être of the Laboratory, how it is dedicated to the study of the cell and molecular biology of cancer and is focused…

Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…

Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…

Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and  the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Healthcare The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges and prospects of medical innovation in the country. Can you please provide an insight into the history and presence of…